Telix Pharmaceuticals (#ASX: $TLX) today announces that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy (BT) designation for Telix’s renal cancer imaging product TLX250-CDx (89Zrgirentuximab). https://t.co/BS621I5gce. #biopharma #cancer #stocks #Medical https://t.co/ydvVKBbiSu